| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IT1-H82W1 | Human | Biotinylated Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free |  |
|
|
| IT1-H52W1 | Human | Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His Tag&Tag Free |  |
|
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo | Tysabri, Antegran, Antegren | Japan | Multiple Sclerosis | Biogen Inc | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Myeloma; Stroke; Crohn Disease | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RBx-7796 | RBx-7796 | Clinical | Sun Pharmaceutical Industries Ltd | Rhinitis, Allergic; Asthma | Details |
| LLP2A alendronate | Phase 1 Clinical | University Of California | Osteoporosis; Bone Diseases | Details | |
| AS-101 | WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101; PRX-0001/AS101 | Phase 2 Clinical | Biomas | Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Condylomata Acuminata; Dermatitis, Atopic | Details |
| 7HP-349 | 7HP-349; 7-HP-349 | Phase 1 Clinical | Solid tumours | Details | |
| ATL-1102 | TV-1102; ATL-1102; ATL/TV-1102; ISIS-107248 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Multiple Sclerosis | Details |
| Natalizumab biosimilar (Polpharma Biologics) | PB-006 | Phase 3 Clinical | Polpharma Biologics | Multiple Sclerosis, Relapsing-Remitting | Details |
This web search service is supported by Google Inc.
A-Z
